Allero Therapeutics is a biotech company that develops next generation immunotherapies for immune disorders like autoimmune -, allergic diseases, and ADA (anti-drug antibodies).
Therapy of immune mediated disorders remains unsatisfactory as current therapies either, do not treat the underlying causes and have significant side effects (autoimmune), or efficacy and compliance is poor (allergy).
Our vision is to improve the quality of life and survival of patients with immune mediated disorders. To achieve this, Allero Therapeutics is on a mission to develop novel targeted treatments that induce antigen-specific tolerance with a long lasting effect.
Allero has received funding from the European Union’s Horizon 2020 research and innovation programme (SME Instrument Phase 1) under grant no 827234 and the EIC Accelerator programme (SME Intrument Phase 2) under grant no 190104468.